Ten Years and Counting: Moving Leucine-Rich RepeatKinase 2 Inhibitors to the Clinic

The Parkinson Disease-linked LRRK2 Protein Mutation I2020T Stabilizes an Active State Conformation Leading to Increased Kinase Activity

(2014) Soumya Ray et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents

(2014) Andrew B. West et al.   JOURNAL OF COMPARATIVE NEUROLOGY

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease

(2014) Mike A Nalls et al.   NATURE GENETICS

Abrogation of  -synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats

(2014) J. P. L. Daher et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domain

(2014) J. Liao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NIH research funding and early career physician scientists: continuing challenges in the 21st century

(2013) Howard H. Garrison et al.   FASEB JOURNAL

LRRK2 secretion in exosomes is regulated by 14-3-3

(2013) K. B. Fraser et al.   HUMAN MOLECULAR GENETICS

Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors

(2013) Yi-Hui Peng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors

(2013) Anthony A. Estrada et al.   JOURNAL OF MEDICINAL CHEMISTRY

The current and projected economic burden of Parkinson's disease in the United States

(2013) Stacey L. Kowal et al.   MOVEMENT DISORDERS

DGIdb: mining the druggable genome

(2013) Malachi Griffith et al.   NATURE METHODS

Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs

(2013) Marco A. S. Baptista et al.   PLoS One

GSK2578215A; A potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor

(2012) Alastair D. Reith et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling

(2012) Huma Q. Rana et al.   GENETICS IN MEDICINE

Neurodegenerative phenotypes in an A53T  -synuclein transgenic mouse model are independent of LRRK2

(2012) J. P. L. Daher et al.   HUMAN MOLECULAR GENETICS

LRRK2 Inhibition Attenuates Microglial Inflammatory Responses

(2012) M. S. Moehle et al.   JOURNAL OF NEUROSCIENCE

High LRRK2 Levels Fail to Induce or Exacerbate Neuronal Alpha-Synucleinopathy in Mouse Brain

(2012) Martin C. Herzig et al.   PLoS One

Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations

(2012) Z. Sheng et al.   Science Translational Medicine

Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database

(2012) Christina M. Lill et al.   PLoS Genetics

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

(2011) Paul Morgan et al.   DRUG DISCOVERY TODAY

LRRK2 Parkinson disease mutations enhance its microtubule association

(2011) Lauren R. Kett et al.   HUMAN MOLECULAR GENETICS

Autophosphorylation in the Leucine-Rich Repeat Kinase 2 (LRRK2) GTPase Domain Modifies Kinase and GTP-Binding Activities

(2011) Philip J. Webber et al.   JOURNAL OF MOLECULAR BIOLOGY

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2

(2011) Xianming Deng et al.   Nature Chemical Biology

Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas

(2011) B. D. Looyenga et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Characterization of the Roco Protein Family in Dictyostelium discoideum

(2010) Wouter N. van Egmond et al.   EUKARYOTIC CELL

Phosphopeptide Analysis Reveals Two Discrete Clusters of Phosphorylation in the N-Terminus and the Roc Domain of the Parkinson-Disease Associated Protein Kinase LRRK2

(2010) Christian Johannes Gloeckner et al.   JOURNAL OF PROTEOME RESEARCH

Microglia Acquire Distinct Activation Profiles Depending on the Degree of α-Synuclein Neuropathology in a rAAV Based Model of Parkinson's Disease

(2010) Vanesa Sanchez-Guajardo et al.   PLoS One

The Parkinson’s disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites

(2009) Elisa Greggio et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Identification of the Autophosphorylation Sites of LRRK2

(2009) Shogo Kamikawaji et al.   BIOCHEMISTRY

LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model

(2009) Javier Alegre-Abarrategui et al.   HUMAN MOLECULAR GENETICS

Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant α-synuclein

(2009) Xian Lin et al.   NEURON

The WD40 Domain Is Required for LRRK2 Neurotoxicity

(2009) Nathan D. Jorgensen et al.   PLoS One

LRRK2 Gly2019Ser penetrance in Arab–Berber patients from Tunisia: a case-control genetic study

(2008) Mary M Hulihan et al.   LANCET NEUROLOGY

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

(2008) Daniel G Healy et al.   LANCET NEUROLOGY